Aberrant DNA methylation in lung cancer: Biological and clinical implications

Oncologist

Volumn 7, Issue 5, 2002, Pages 451-457

  Zöchbauer Müller, Sabine ^a,c   Minna, John D ^b   Gazdar, Adi F ^b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Lung cancer; Methylation; Preneoplastic lesion; Risk assessment; Tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE DEACETYLASE; TRICHOSTATIN A;

ARTICLE; BRONCHUS MUCOSA; CANCER RISK; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL TRIAL; DEMETHYLATION; DIAGNOSTIC VALUE; DISEASE MARKER; DNA METHYLATION; DNA SEQUENCE; GENE INACTIVATION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

DNA METHYLATION; DNA, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; RISK ASSESSMENT; SMOKING; SPUTUM; TUMOR MARKERS, BIOLOGICAL;

EID: 0036411838     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-5-451     Document Type: Article

References (48)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
2. Antequera F, Bird A. CpG islands. EXS 1993;64:169-185.
3. Baylin SB, Esteller M, Rountree MR et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-692.
4. Herman JG, Graff JR, Myöhänen S et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
5. Virmani AK, Müller C, Rathi A et al. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 2001;7:584-589.
6. Eads CA, Danenberg KD, Kawakami K et al. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 1999;59:2302-2306.
7. Eads CA, Danenberg KD, Kawakami K et al. MethyLight: A high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
8. Brabender J, Usadel H, Danenberg KD et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 2001;20:3528-3532.
9. Gebert JF, Moghal N, Frangioni JV et al. High frequency of retinoic acid receptor beta abnormalities in human lung cancer. Oncogene 1991;6:1859-1868.
10. Geradts J, Chen JY, Russell EK et al. Human lung cancer cell lines exhibit resistance to retinoic acid treatment. Cell Growth Differ 1993;4:799-809.
11. Lu XP, Fanjul A, Picard N et al. Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nat Med 1997;3:686-690.
12. Xu XC, Sozzi G, Lee JS et al. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: Implications for lung cancer development. J Natl Cancer Inst 1997;89:624-629.
13. Xu XC, Lee JS, Lee JJ et al. Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention. J Natl Cancer Inst 1999;91:1317-1321.
14. Ayoub J, Jean-Francois R, Cormier Y et al. Placebo-controlled trial of 13-cis-retinoic acid activity on retinoic acid receptor-beta expression in a population at high risk: Implications for chemoprevention of lung cancer. J Clin Oncol 1999;17:3546-3552.
15. Picard E, Seguin C, Monhoven N et al. Expression of retinoid receptor genes and proteins in non-small-cell lung cancer [see comments]. J Natl Cancer Inst 1999;91:1059-1066.
16. Virmani AK, Rathi A, Zöchbauer-Müller S et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303-1307.
17. Dammann R, Li C, Yoon JH et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-319.
18. Burbee DG, Forgacs E, Zöchbauer-Müller S et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-699.
19. Dammann R, Takahashi T, Pfeifer GP. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 2001;20:3563-3567.
20. Sozzi G, Veronese ML, Negrini M et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
21. Fong KM, Biesterveld EJ, Virmani A et al. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 1997;57:2256-2267.
22. Sozzi G, Sard L, De Gregorio L et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 1997;57:2121-2123.
23. Geradts J, Fong KM, Zimmerman PV et al. Loss of Fhit expression in non-small-cell lung cancer: Correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer 2000;82:1191-1197.
24. Zöchbauer-Müller S, Fong KM, Maitra A et al. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001;61:3581-3585.
25. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-1455.
26. Toyooka KO, Toyooka S, Virmani AK et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 2001;61:4556-4560.
27. Toyooka S, Toyooka KO, Maruyama R et al. DNA methylation profiles of lung tumors. Mol Cancer Therapeutics 2001;1:61-67.
28. Virmani AK, Rathi A, Sathyanarayana UG et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001;7:1998-2004.
29. Serrano M, Lee H, Chin L et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
30. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.
31. Zöchbauer-Müller S, Fong KM, Virmani AK et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249-255.
32. Esteller M, Corn PG, Baylin SB et al. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-3229.
33. Kashiwabara K, Oyama T, Sano T et al. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int J Cancer 1998;79:215-220.
34. Belinsky SA, Nikula KJ, Palmisano WA et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11891-11896.
35. Esteller M, Sanchez-Cespedes M, Rosell R et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
36. Usadel H, Brabender J, Danenberg KD et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002;62:371-375.
37. Kersting M, Friedl C, Kraus A et al. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000;18:3221-3229.
38. Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-5958.
39. Gazdar AF, Zöchbauer-Müller S, Virmani A et al. RESPONSE Re: Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 2001;93:67-68.
40. Soria JC, Rodriguez M, Liu DD et al. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res 2002;62:351-355.
41. Tang X, Khuri FR, Lee JJ et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1511-1516.
42. Kim DH, Nelson HH, Wiencke JK et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-3424.
43. Momparler RL, Bouffard DY, Momparler LF et al. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997;8:358-368.
44. Momparler RL, Eliopoulos N, Ayoub J. Evaluation of an inhibitor of DNA methylation, 5-aza-2′-deoxycytidine, for the treatment of lung cancer and the future role of gene therapy. Adv Exp Med Biol 2000;465:433-446.
45. Cameron EE, Bachman KE, Myohanen S et al. Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat Genet 1999;21:103-107.
46. Bovenzi V, Momparler RL. Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol 2001;48:71-76.
47. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications. Ann Intern Med 2001;134:573-586.
48. Sandor V, Bakke S, Robey RW et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-728.